Anixa Biosciences Issues Update On Patient Outcomes Observed In Ongoing Phase 1 Ovarian Cancer CAR-T Clinical Trial, Following Regulatory Approval Of Protocol Amendment That Enables Substantial Dose Escalation
Benzinga Newsdesk 8 months ago
News
Multiple patients substantially exceed expected survival at low dose levels; absence of dose-limiting toxicities supports escalation to doses up to 100x higherTrial expansion reflects growing confidence in
Multiple patients substantially exceed expected survival at low dose levels; absence of dose-
limiting toxicities supports escalation to doses up to 100x higher
Trial expansion reflects growing confidence in intra-peritoneal CAR-T delivery and introduces
lymphodepletion to potentially enhance efficacy
Anixa to participate in Water Tower Research fireside chat at 11:00am ET on February 10, 2026
to discuss trial observations
SAN JOSE, Calif., Feb. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today provided an update on patient outcomes observed in its ongoing Phase 1 ovarian cancer CAR-T clinical trial, following regulatory approval of a protocol amendment that enables substantial dose escalation.